Enlicitide (decanoate)

Overview

Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9 , blocks its interaction with low-density lipoprotein receptor ( LDLR ), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol , apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease .

Application

Products | Products > Peptides | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Chronic Disease and Inflammation | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Atherosclerosis and Inflammation | Products > Disease Areas > Hypercholesterolemia | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > PCSK9

Product Information

• Catalog No.: HY-W1126955
• CAS No.: 2861205-06-1
• Molecular Formula: C92H129FN14O17
• Molecular Weight: 1722.09
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source